"Dr. Schoemaker has made an indelible mark on the world's biotechnology industry, and he is one of the founders of our vibrant community in Pennsylvania," said Fritz Bittenbender, president of Pennsylvania Bio. "Dr. Schoemaker has improved the lives of patients globally, while inspiring the next generation of entrepreneurs and scientists. In 2004, Centocor, Inc., co-founded by Dr. Schoemaker, celebrated its 25th anniversary and stands as one of our industry's great success stories. Dr. Schoemaker's influence is felt through the many people he inspired to become leaders and innovators in this industry, and his pioneering spirit is seen not only in Centocor, but also Neuronyx, Inc., the second company he founded."
Dr. Schoemaker is among the biotechnology industry's leading scientists and entrepreneurs. He founded Centocor, Inc., one of Pennsylvania's first biotechnology companies as well as one of the industry's great successes, in 1979, serving as chairman of its Board of Directors until 1999. In 1999, following the acquisition of Centocor by Johnson & Johnson, he founded Neuronyx, Inc., a development-stage biopharmaceutical company located in Malvern, Pennsylvania.
"Neuronyx has been a direct beneficiary of Hubert's vision and wisdom in building life sciences companies. His experience has had a direct or indirect impact on everyone involved in the life sciences community in Southeastern Pennsylvania," said Stephen Webster, president and CEO of Neuronyx, Inc.
Dr. Schoemaker is widely noted as an inspiration and mentor to many industry CEOs, scientists and executives. As chairman of Centocor, he was responsible for identifying, developing and commercializing diagnostic and therapeutic products, as well as providing oversight and direction on scientific and technical issues. But it was his strong business skills that enabled him to guide Centocor from a fledgling start-up to a profitable publicly traded company. He shepherded Centocor through a major setback in 1992, when the U.S. Food and Drug Administration did not approve the company's first drug, to its 1994 success, when the FDA approved ReoPro(R), a drug to reduce heart attacks in patients who have had angioplasty, and its 1998-99 milestone when the FDA approved Remicade(R) for Crohn's disease and rheumatoid arthritis.
In 1994, he was diagnosed with a fast-growing and usually fatal brain cancer, but he became one of just a handful of adult survivors. A true entrepreneur, Dr. Schoemaker then turned his attention to founding his second company, Neuronyx, Inc., where he is currently a director.
Dr. Schoemaker holds a B.S. in chemistry from the University of Notre Dame and a Ph.D. in biochemistry from the Massachusetts Institute of Technology. He is a founder and co-chairman of the Board of the Technology Leaders Venture Capital Fund, directing Technology Leaders I and Technology Leaders II. He has made enormous contributions to the community as a member of the Board of Trustees of the Franklin Institute, the University of the Arts, and the National Research Council Committee on Japan. Dr. Schoemaker is a member of the Melmark Board of Directors, among many others. He has delivered more than 100 presentations, and has contributed more than 20 articles to publications.
Pennsylvania Bio's Annual Dinner is the statewide celebration of the biosciences community in Pennsylvania. Approximately 500 professionals involved in the industry are expected to attend what will be the largest dinner to date. The Annual Dinner is being sponsored by Pepper Hamilton LLP and VWR International, and the opening reception is being sponsored by Wyeth.
About Pennsylvania Bio
Pennsylvania Bio is a catalyst to ensure Pennsylvania is a global leader in biosciences by developing a cohesive community that unites the region's biotechnology, pharmaceutical, research, and financial strengths.